Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis
touchREVIEWS in Endocrinology · 2024
DOI: 10.17925/ee.2024.20.2.10 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift touchREVIEWS in Endocrinology, 2024. Verfasst von Deep Dutta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, CEDAR Superspeciality Healthcare, Dwarka, New Delhi, India. Die Arbeit wurde bisher 18-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To date, no meta-analysis has analyzed the efficacy and safety of tirzepatide as an anti-obesity medication in individuals without diabetes. This meta-analysis was undertaken to address this knowledge gap. Materials and methods: Electronic databases were searched for randomized controlled trials (RCTs) involving individuals with obesity without diabetes receiving tirzepatide in the intervention arm and placebo in the control arm. The primary outcome was the percentage change in weight from baseline, and the secondary outcomes included the change in weight from baseline; a weight reduction of ≥5%, ≥10%, ≥15%, ≥20% and ≥25%; glycaemic parameters; lipid parameters and adverse events.
Results
From 281 initially screened articles, data from 2 RCTs involving 1,852 participants were analyzed. The efficacy and safety of tirzepatide 15 mg (or the highest tolerable dose) versus placebo were analyzed. The percentage change in body weight was higher with tirzepatide than with placebo (mean difference [MD]: -19.44%; 95% confidence interval [CI]: -22.48 to -16.41; p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology, CEDAR Superspeciality Healthcare, Dwarka, New Delhi, India.
- Department of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh.
- Department of Endocrinology, JSS Medical College, JSS Academy of Higher Education Research, Mysore, India.
- Department of Endocrinology, Indraprastha Apollo Hospitals, New Delhi, India.
Zitieren
APA
Dutta, D., Kamrul-Hasan, A. B. M., Nagendra, L., & Bhattacharya, S. (2024). Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis. touchREVIEWS in Endocrinology. https://doi.org/10.17925/ee.2024.20.2.10
Vancouver
Dutta D, Kamrul-Hasan ABM, Nagendra L, Bhattacharya S. Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis. touchREVIEWS in Endocrinology. 2024. doi:10.17925/ee.2024.20.2.10
BibTeX
@article{Dutta2024,
author = {Dutta, Deep and Kamrul-Hasan, A B M and Nagendra, Lakshmi and Bhattacharya, Saptarshi},
title = {Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis},
journal = {touchREVIEWS in Endocrinology},
year = {2024},
doi = {10.17925/ee.2024.20.2.10}
}
EUVIMED